1. Market Research
  2. > Therapy Market Trends
  3. > Sodium-Glucose Co-Transporter 2 Inhibitor Industry

Sodium-Glucose Co-Transporter 2 Inhibitor Industry Statistics

You might be interested in: Diabetes, Hospital, Pharmaceutical, Type 2 Diabetes, Cardiovascular Disease, Therapy, Antidiabetics, Insulin, Biguanide, Glucagon Like Peptide 1 Receptor Activator, Gliptins, Targeted Therapy, Glinides, Opioid, Thiazolidinedione, Chemotherapy, Monoclonal Antibody, Analgesic, Anti-Infective, Antipsychotic.

1-10 of about 100 reports for Sodium-Glucose Co-Transpo...

Therapy and Antidiabetics Market in the UK

  • January 2017
    254 pages
  • Therapy  

    Antidiabetics  

    Sodium-Glucose ...  

  • United Kingdom  

View report >

Global Antidiabetics Market

  • January 2017
    8 pages
  • Antidiabetics  

  • World  

    Thailand  

View report >

Antidiabetics Market in the UK

  • November 2017
    57 pages
  • Antidiabetics  

    Insulin  

    Biguanide  

  • United Kingdom  

View report >

Tuberculosis Statistics in the UK

  • September 2016
    70 pages
  • Tuberculosis  

    Infectious Dise...  

    Hepatitis  

  • United Kingdom  

View report >

Antidiabetics Market in the US

  • May 2017
    34 pages
  • Antidiabetics  

    Biguanide  

    Therapy  

  • United States  

View report >

Antidiabetics Market in the US

  • May 2017
    40 pages
  • Antidiabetics  

    Biguanide  

    Therapy  

  • United States  

View report >

Biguanide Market

  • May 2017
    40 pages
  • Antidiabetics  

    Biguanide  

    Thiazolidinedio...  

View report >

Insulin Market in the US

  • January 2017
    16 pages
  • Insulin  

    Antidiabetics  

    Diabetes  

  • United States  

View report >

Insulin Market and Endocrine Disease Statistics in South Africa

  • January 2017
    198 pages
  • Insulin  

    Antidiabetics  

    Endocrine Disea...  

  • South Africa  

View report >
1 report for Sodium-Glucose Co-Transpo...

Purchase Reports From Reputable Market Research Publishers

Drug Analysis: Invokana

Drug Analysis: Invokana

  • $ 10000
  • Industry report
  • February 2018
  • by Datamonitor Healthcare

Drug OverviewInvokana (canagliflozin; Johnson and Johnson/Mitsubishi Tanabe/Daiichi Sankyo) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. SGLT-2 inhibitors do not target ...


ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on